SCHEMBL19410285

SCHEMBL19410285

O=[N+]([O-])c1ccc2[nH]ccc2c1.O=[N+]([O-])c1cccc2[nH]ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
GAA P10253 2/20 0.43
GFER P55789 1/20 0.43
CTSV O60911 1/20 0.42
CTSL P07711 1/20 0.42
POLB P06746 3/20 0.41
NOS1 P29475 2/20 0.41
MAPT P10636 2/20 0.41
MAOB P27338 1/20 0.41
PKM P14618 1/20 0.41
PKLR P30613 1/20 0.41
TDP1 Q9NUW8 2/20 0.41
CYP19A1 P11511 1/20 0.41
NPC1 O15118 2/20 0.40
TSHR P16473 2/20 0.40
ALOX5 P09917 1/20 0.39
LMNA P02545 2/20 0.39
HSP90AA1 P07900 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21496937 0.89 ALDH1A1 (0.48) ALDH1A1MEN1KMT2AGAAGFER
SCHEMBL28686 0.84 MAPT (0.54) ALDH1A1GAAPOLBNOS1MAPT
SCHEMBL29471420 0.84 ALDH1A1 (0.64) ALDH1A1MEN1KMT2AGAAGFER
SCHEMBL28549 0.84 ALDH1A1 (0.64) ALDH1A1MEN1KMT2AGAAGFER
SCHEMBL30597526 0.84 MAPT (0.54) ALDH1A1GAAPOLBNOS1MAPT
Methane SCHEMBL27929615 0.82 MAPT (0.53) ALDH1A1GAAPOLBNOS1MAPT
Ammonia Solution, Strong SCHEMBL28394313 0.82 MAPT (0.53) ALDH1A1GAAPOLBNOS1MAPT
SCHEMBL8178724 0.79 ALDH1A1 (0.41) ALDH1A1MEN1KMT2AGAAGFER
Phosphoric Acid SCHEMBL594274 0.77 MAPT (0.47) GAAPOLBNOS1MAPTMAOB
Pyridine SCHEMBL28517154 0.76 MAPT (0.48) POLBNOS1MAPTMAOBCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10876121-B2 EGFR nucleic acids and uses thereof AVIDITY BIOSCIENCES, INC. (US) 2020-12-29 US disclosed
US-10858656-B2 KRAS nucleic acids and uses thereof AVIDITY BIOSCIENCES, INC. (US) 2020-12-08 US disclosed
US-20170362597-A1 EGFR NUCLEIC ACIDS AND USES THEREOF AVIDITY BIOSCIENCES, INC. 2017-12-21 US disclosed
US-20170283476-A1 MYC NUCLEIC ACIDS AND USES THEREOF AVIDITY BIOSCIENCES, INC. 2017-10-05 US disclosed
US-20170283806-A1 KRAS NUCLEIC ACIDS AND USES THEREOF AVIDITY BIOSCIENCES, INC. 2017-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170283476-A1 MYC NUCLEIC ACIDS AND USES THEREOF MYC, MYCBP, MYCBP2 ALDH1A1 3433/4885MEN1 1070/4885KMT2A 1006/4885
US-10876121-B2 EGFR nucleic acids and uses thereof EGFR, ERBB3, ERBB2 ALDH1A1 3983/4885MEN1 4283/4885KMT2A 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.